New CDH3 mutation in the first Spanish case of hypotrichosis with juvenile macular dystrophy, a case report

Fiona Blanco-Kelly¹,², Luciana Rodrigues-Jacy da Silva¹, Iker Sanchez-Navarro¹, Rosa Riveiro-Alvarez¹,², Miguel Angel Lopez-Martinez¹, Marta Corton¹,² and Carmen Ayuso¹,²,³*

Abstract

Background: CDH3 on 16q22.1 is responsible for two rare autosomal recessive disorders with hypotrichosis and progressive macular dystrophy: Hypotrichosis with Juvenile Macular Dystrophy and Ectodermal Dysplasia, Ectrodactyly and Macular Dystrophy. We present a new case of Hypotrichosis with Juvenile Macular Dystrophy.

Case presentation: A Spanish male born in 1998 from non-consanguineous healthy parents with a suspected diagnosis of Keratosis Follicularis Spinulosa Decalvans and Retinitis Pigmentosa Inversa referred to our Genetics Department (IIS-Fundación Jiménez Díaz).

Molecular study of ABCA4 was performed, and a heterozygous missense p.Val2050Leu variant in ABCA4 was found. Clinical revision reclassified this patient as Hypotrichosis with Juvenile Macular Dystrophy. Therefore, further CDH3 sequencing was performed showing a novel maternal missense change p.Val205Met (probably pathogenic by in silico analysis), and a previously reported paternal frameshift c.830del;p.Gly277Alafs*20, thus supporting the clinical diagnosis.

Conclusions: This is not only the first Spanish case with this clinical and molecular diagnosis, but a new mutation has been described in CDH3. Moreover, this work reflects the importance of joint assessment of clinical signs and evaluation of pedigree for a correct genetic study approach and diagnostic.

Keywords: Macular dystrophy, CDH3, Hypotrichosis, Syndromic retinal dystrophy, Case report

Background

The CDH3 gene, on16q22.1, encodes for P-cadherin, which is expressed in retina epithelial cells and in hair follicles, being responsible for adherens junctions (calcium dependent cell-cell adhesion molecule) in these and other epithelial tissues [1, 2]. Additionally, CDH3 is thought to be a marker of the epithelial tissues progenitor cells and it has been found to be expressed in human embryonic stem cells [3, 4]. This gene is responsible for two rare autosomal recessive disorders: Hypotrichosis with Juvenile Macular Dystrophy (HJMD, OMIM: 601553) [5–17] and Ectodermal Dysplasia, Ectrodactyly and Macular Dystrophy (EEM, OMIM: 225280) [18]. Both disorders characterized by hypotrichosis and progressive retinal dystrophy.

To date, according to Orphanet (http://www.orpha.net, date of access 11/05/2016) the frequencies of HJMD and EEM are unknown and across the world only 50 cases of HJMD and approximately 15 cases of EEM (only three with molecular characterization) [8, 19] have been described.

HJMD has been described as macular degeneration and short sparse scalp hair from birth with hair loss during the first months of life [5]. The retinal phenotype is nowadays being re-evaluated. It has been suggested that earlier onset is more likely than the juvenile stated on its name [7, 20–22], and that there is a wider involvement of the retina (not only the macula) [7, 20–23]. Thus,
defining the retinal alteration as a more complex retinal dystrophy rather than a solely macular dystrophy.

The hair can present different types of abnormalities being pili-torti one of the most frequent (twisted hair shafts on the long axis, which are brittle, and break at varying lengths with many areas appearing bald) [5, 24]. It usually affects the scalp but can also affect eyebrows and eyelashes (body hair is normal) [5, 24].

Patients with EEM syndrome, additionally exhibit a wider range of features such as split hand/foot malformation (SHFM) or ectrodactyly along or not with oligodontia, enamel hypoplasia, and widely spaced teeth [18]. The presence of minimal limb abnormalities has been described in one HJMD patient [6].

Our aim is to present the first Spanish case with HJMD due to mutations in the \(CDH3\) gene and the importance of an accurate genetic and clinical diagnosis.

**Case presentation**

A male born in 1998, from the north east of Spain was referred to Clinical Genetics with a diagnosis of Keratosis Follicularis Spinulosa Decalvans (OMIM 308800, probable Siemens Syndrome) and Retinitis Pigmentosa Inversa. He was referred in 2011 to the Department of Medical Genetics at the Fundación Jiménez Díaz University Hospital for genetic study. The parents and a nine year old brother were alive and healthy. Nothing of note was reported at a family level, and neither consanguinity nor endogamy existed (Fig. 1. Pedigree).

The Dermatological report stated absence of growing hair since the 1st year of age, pale skin, sparse scalp hair, punctiform follicular keratosis on cheeks, forehead, eyebrows and anterior surface of the arms and posterior surface of the legs, erythema with follicular hyperkeratosis and reduction of hair density on eyebrows.

A skin biopsy had been performed, and was informed as presenting a reduction in the number of scalp follicles, absence of seborrheic glands and infundibular cyst with keratin granules. The suspected diagnosis was Keratosis Follicularis Spinulosa Decalvans (Siemens syndrome).

The patient had been diagnosed with retinal alteration at the age of two (no other data was available). Further ophthalmological examination reports were available for ages four, ten and twelve (Table 1).

The patient underwent an excision of a pedunculated colorectal polyp and had been diagnosed with Nodular Lymphoid Hyperplasia of the gastrointestinal tract at the age of two.

The patient was first referred to our Department for genetic testing (reports and sample) in 2011, with a diagnosis of two unrelated diagnosis, Siemens Syndrome and Retinitis Pigmentosa Inversa, for testing of the retinal dystrophy. Further, he was seen at Clinics at the

---

**Fig. 1** Clinical Genetics' examination and Pedigree. **a-e** Clinical Genetics' examination: pale and dry skin, hypotrichosis of scalp and face (**a-c**). Scalp hair: blond and brittle (impression of pili torti) (**a** and **B**). Pigmented lesions in face impressive of keratosis and centro-facial lentigine (**B** and **C**). No limbs anomalies (**d** and **e**). Pedigree: Wt = wild type
Department of Genetics at the age of 14 and 15 (Table 2), when his diagnosis was re-assessed as likely presenting HJMD, which accounted for both conditions (both the retinal dystrophy and the hypotrichosis).

Clinical Genetics examination at the age of 14 and 15 revealed generalised pale and dry skin, hypotrichosis that was confined to scalp, face (no incipient beard nor moustache at the age of 16) and arms (Fig. 1 a-e). Scalp hair was blond and brittle (impression of *pili torti*) (Fig. 1a), eyebrows and eyelashes (not shown) appeared normal; although at a younger age a reduction in their density had been described. Pigmented lesions could be observed in face, they were impressive of keratosis and centro-facial lentigine and to our knowledge they were probably sun exposure related (Fig. 1b and c). No dental, hands or feet anomalies were noticed (Fig. 1d and e); when asked, the patient denied needing special dental care. No other findings were manifest after complete clinical examination.

First suspected diagnosis, based on the referral information, was *ABCA4*-related maculopathy + Keratitis Follicularis Spinulosa Decalvans. However, after clinical examination and further evaluation of the reports, the suspected diagnosis was HJMD.

An automated DNA extractor (model BioRobot EZ1; Qiagen, Hilden, Germany) was used for DNA extraction from peripheral blood collected in EDTA tubes in accordance with manufacturer instructions.

For the study of *ABCA4* gene the following techniques were used: a) Genotyping APEX (Arrayed Primer Extension) for *ABCA4* gene (Asper biotech, Tartu, Estonia, http://www.asperbio.com/asper-ophthalmics/stargardt-disease-cone-rod-dystrophy-abca4/stargardt-disease-targeted-mutation-analysis); b) Sanger sequencing of all the coding exons and intronic flanking sequences, and c) MLPA (Multiplex Ligation-dependent Probe Amplification) analysis using a commercial kit (SALSA® MLPA® P151-P152 *ABCA4* probemix, MRC-Holland, Amsterdam, the Netherland) to study *ABCA4* exonic deletions or duplications. b) And c) where analyzed by capillary electrophoresis (*Abiprism 3130; Sequencing Analysis* v5.2), performed at our Genetics Department, Fundación Jiménez Díaz University Hospital, Madrid.

For the study of the *CDH3* gene a Sanger sequencing of all the coding exons and intronic flanking sequences of *CDH3* was performed at Imegen (Instituto de Medicina Genómica, Valencia, Spain).

For confirmation and segregation of the changes found in *CDH3*, Sanger sequencing was performed at our Genetics Department. The brother was not studied as the majority of international guidelines addressing genetic carrier testing in children do not recommend it. However, we did recommend that when he becomes an adult, a carrier testing (for both *ABCA4* and *CDH3*) is performed.

First, and based on the initial clinical suspicion of two different conditions being present in the patient (patient was referred along with the sample for retinal dystrophy testing as presenting two unrelated entities), a study of isolated juvenile macular dystrophy was performed. Only

**Table 1** Patient’s ophthalmological examinations since the age of four

| Age    | Visual Acuity and Visual Field (RE/LE) | Ophthalmoscopy | VEP | Electoretinogram |
|--------|----------------------------------------|----------------|-----|------------------|
| 4 years | First symptoms: reduction of VA and central VF; VA: 0.1/0.1 (4 years) | Macular alteration with spicules BE | NA  | NA               |
| 10 years| NA                                     | NA             | Abnormal | RE: scotopic: normal, cones response: lower limit of normality; LE: moderate decline of all responses |
| 12 years| VA 0.15/0.15. VF: Loss of the central 20° and 10° RE and LE respectively, conserved peripheral field | Macular atrophy with pigment accumulation BE | NA  | NA               |

**Table 2** Timeline

| Year (age in years) | Event |
|---------------------|-------|
| 2000                | -First visit to Dermatology due to absence of hair growth 
|-Excision of a pedunculated colorectal polyp: Nodular Lymphoid Hyperplasia of the gastrointestinal tract |
| 2002 (4)            | -First visit to Ophthalmology: Maculopathy was suspected |
| 2003 (5)            | -Maculopathy vs inverse retinitis pigmentosa 
|-Skin biopsy: Suspection of Keratosis Follicularis Spinulosa Decalvans (Siemens Syndrome) |
| 2005 (7)-2010 (12)  | -Ophthalmological follow up |
| 2011 (13)           | -Referral for Genetic testing (bloods and reprints): clinical suspicion *ABCA4*-related maculopathy + Keratitis Follicularis Spinulosa Decalvans - Genetic tests: APEX (Arrayed Primer Extension) chip, sequencing and MLPS (multiplex ligation-dependent probe amplification) for *ABCA4* gene: heterozygous for c.6148G > C, p.Val2050Leu. No second allele was found |
| 2012 (14)           | -First visit to Clinical Genetics, diagnosis re-assessment: Hypotrichosis with Juvenile Macular Dystrophy |
| 2013 (15)           | -Genetic Tests: *CDH3* sequencing: c.830del; p.Gly277Alafs*20 (paternal) and c.613G > A; p.Val205Met (maternal) 
|-2nd visit to Clinical Genetics, confirmed diagnosis: Hypotrichosis with Juvenile Macular Dystrophy due to *CDH3* mutations |
a heterozygous missense mutation (c.6148G>C, p.Val2050Leu; NM_000350 RefSeq) in ABCA4 was found. After a comprehensive analysis of coding regions and gene rearrangements a second allele was not found.

Further, and after the re-assessment of the patient on his appointment at Clinical Genetics, CDH3 (NM_001793.5 RefSeq) sequencing allowed to detect compound heterozygous variants: a novel maternal missense change c.613G>A; p.Val205Met, predicted as probably pathogenic by in silico analysis (dataset dbnsfp30a implemented in ANNOVAR was used. (Table 3), and a previously reported paternal frameshift c.830del; p.Gly277Alafs*20 [7].

Several evidences strongly support that p.Val205Met in CDH3 is a very likely pathogenic variant and seems to be responsible for our patient’s clinical findings: a) high evolutionary conservation of the amino-acid residue that is located at a calcium-binding site (sites crucial for function and stability of cadherins [25], Fig. 2a and b), b) an in silico damaging effect on the protein is predicted in 10 out of 12 in silico tools, (Table 3), c) its absence in ExAC database (http://exac.broadinstitute.org/gene/ENSG00000062038, date of access 04/04/2016), d) the is change co-segregating with the disease, and e) a phenotype highly suggestive of CDH3.

This way, clinical revision along with directed genetic study allowed reclassifying this patient as HJMD due to CDH3 mutation.

Conclusions

We have presented a patient with a phenotype of HJMD. The fact that no other alterations were observed, apart from retinal dystrophy and hypotrichosis, allowed us to discard EEM. Although no radiological examination of hand or feet was performed, which would completely rule out EEM, on clinical examination no abnormality was noted. Mild anomalies of hand and feet have been noted in EEM patients misdiagnosed with HJMD [6, 19], we believe that this is not the case in our patient. Mild changes (as subtle shortening of distal phalanges or mild toe syndactyly) were not observable on the thorough clinical examination, performed on our patient.

The presence of two compound heterozygous mutations in the CDH3 gene in our patient, supported our clinical suspicion.

The ABCA4 gene was studied because it is the most frequent gene responsible for macular dystrophy in the young [26] and the retinal phenotype stated in the available reports were suggestive of macular dystrophy. As previously mentioned, first suspected diagnosis, based on the referral information, was ABCA4—related maculopathy + Keratosis Follicularis Spinulosa Decalvans. Even if our patient presented a mutation on the ABCA4 gene, it was discarded as responsible for the patient’s maculopathy as no second mutation was found. We cannot rule out that the p.Val2050Leu mutation in ABCA4 is playing a role in the patient’s ophthalmological phenotype. However, there is no known functional interaction between ABCA4 and CDH3 at a genetic or protein level; and, the pathogenic effect of the p.Val2050Leu change in ABCA4 is nowadays discussed (http://www.ncbi.nlm.nih.gov/clinvar/?term=%22Retina%20International%22[-submitter]+AND+%22ABCA4%22[gene], date of access 04/04/2016). Additionally, the prevalence of patients affected by retinal dystrophy carrying an ABCA4 mutation with another causative gene for their retinal dystrophy is not rare [27].

As it has previously been noted the main differential diagnostic of HJMD from an ophthalmological point of view is not only Stargardt’s disease, which is caused mainly by ABCA4 mutations [20], but any retinal dystrophy phenotype suggestive of CDH3, regardless of the hair phenotype [22]. However, when patients access a Clinical Genetics Department they have to be evaluated as a whole. The presence of two genetic disorders in a given patient, one being retinal dystrophy may occur [28]. Nevertheless, in these co-occurrence cases, it is more likely that the different signs and symptoms are due to the same genetic cause.

Nowadays, performing an accurate diagnosis is essential since cell and gene therapy are being evaluated in retinal dystrophies [29, 30], and phenotypic and genetic characteristics are to be considered when selecting patients for future treatments [23].

Besides, the suspected dermatological diagnosis (Siemens Syndrome, OMIM: 305100) is an X-linked trait
and has additional skin changes, not present in our patient. Therefore, the patient’s pedigree and phenotype were unlikely to suggest this inheritance model and diagnosis.

Interestingly, our patient’s retinal alteration was first noticed when he was two years of age and he was diagnosed as presenting Retinitis Pigmentosa Inversa. This fact supports the idea of an early onset retinal dystrophy rather than a juvenile onset, and the existence of a major implication of the retina beyond the macula [7, 20–23].

Despite the fact that the missense change p.Val205Met in CDH3 has not been reported previously, we have presented evidence of its pathogenicity. Moreover, a missense change has been described in the same aminoacid position (p.Val205Leu) with a minor allele frequency of $2 \times 10^{-5}$ in Asian and Latino populations (http://exac.broadinstitute.org/gene/ENSG00000062038, date of access 04/04/2016).

To date, the CDH3 gene is the only gene known to be responsible for HJMD. HJMD is a very rare disease, fact that makes both its clinical and genetic diagnosis difficult. However, clinical aspects when taken together should guide us to a clinical diagnosis and lead to us to the specific genetic test to be performed.

The presence of two compound heterozygous mutations in this gene in our patient with a phenotype highly suggestive of HJMD and the absence of additional systemic anomalies led us to the diagnosis of the first Spanish case, and one of the very few Caucasian cases, of HJMD and to describe a new mutation in the CDH3 gene.

Moreover, not only we prove that an accurate clinical genetic diagnosis is of crucial relevance for leading directed genetic studies, but we have widened the number of both HJMD cases and CDH3 mutations.

Additionally, we also present the importance of differential diagnosis in retinal dystrophies (syndromic or not) as prognosis, follow up, chance of treatment and familiar implications are deeply linked to the responsible gene.

Abbreviations
BE: Both eyes; EEM: Ectodermal dysplasia, ectrodactyly and macular dystrophy; HJMD: Hypotrichosis with juvenile macular dystrophy; LE: Left eye; MLPA: multiplex ligation-dependent probe amplification; RD: Retinal dystrophy; RE: Right eye; SHFM: split hand/foot malformation; VA: Visual acuity; VEP: Visual evoked potentials; VF: Visual field; Yr: Years

Acknowledgements
The authors would like to thank the patient and his family for their invaluable collaboration, and Dra Mª Antonia Ardanaz Aldabe and Dr Ignacio Yanguas Bayona for their initial management of the patient.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Funding
The following research grants have supported the work leading to this publication: FEDER (European Regional Development Fund), Fondo de Investigación Sanitaria -FIS- (PI13/00226), the Centre for Biomedical Network Research on Rare Diseases -CIBERER- (06/07/0036), the Biobank of University Hospital Fundación Jiménez Díaz Hospital (PT13/0010/0012), ONCE (Organización Nacional de Ciegos Españoles), MC by Miguel Servet Grant CP13/03256 and ISN by Sara Borrell Grant CD13-00085.

Authors’ contributions
FBK and CA had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. LRJdS, MC, FBK and CA contributed to the study concept and design. FBK, MC, ISN and CA were responsible for drafting of the manuscript. A critical revision of the manuscript for important intellectual content was...
carried out by FBK, ISN, MC and CA. FBK, MC and CA were responsible for the study supervision. L.RdS, RRA and MALM contributed to the administrative, technical and material support. All Authors contributed to the acquisition, analysis and interpretation of data. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
The participants included in the study signed a written informed consent to publish their data (parents signed in the behalf of the proband).

Ethics approval and consent to participate
The research protocols, in accordance with the tenets of the Declaration of Helsinki and their reviews, were approved by the Ethics Committee of the University Hospital Fundación Jiménez Díaz. The three individuals included in the study signed a written informed consent to participate in the study (parents signed in the behalf of the proband).

Additional informed consent was obtained from the parents on the behalf of the proband, for whom identifying information is included in this article.

Author details
1Department of Medical Genetics, Instituto de Investigación Sanitaria - Fundación Jiménez Díaz, (IIS-FJD, UAM), Madrid, Spain. 2Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto Carlos III (ISCIII), Madrid, Spain. 3Department of Genomics and Genetics, Fundación Jiménez Díaz University Hospital, Av. Reyes Católicos nº 2, 28040 Madrid, Spain.

Received: 26 August 2016 Accepted: 21 December 2016

Published online: 07 January 2017

References
1. Perez-Moreno M, Jamora C, Fuchs E. Sticky business: orchestrating cellular signals at adherens junctions. Cell. 2003;112(4):534–48.
2. Shimomura Y, Wajid M, Shapiro L, Christiano AM. P-cadherin is a p63 target gene with a crucial role in the developing human limb bud and hair follicle. Development. 2008;135(4):743–53.
3. Kolle G, Ho M, Zhou Q, Chy HS, Krishnan K, Cloonan N, et al. Identification of human embryonic stem cell surface markers by combined membrane-polyacrylamide gel electrophoresis and immunotranscriptional profiling. Stem Cells. 2009;27(10):2446–52.
4. Radice GL, Ferreira-Cornwell MC, Robinson SD, Rayburn H, Chodosh LA, Takeichi M, et al. Precocious mammary gland development in P-cadherin-deficient mice. J Cell Biol. 1997;139(4):1025–32.
5. Indelman M, Bergman R, Lurie R, Richard G, Miller B, Petronius D, et al. A missense mutation in CDH3, encoding P-cadherin, causes hypotrichosis with juvenile macular dystrophy. J Invest Dermatol. 2002;119(5):1210–1.
6. Indelman M, Eason J, Hummel M, Loza O, Suri M, Leys MJ, et al. Novel CDH3 mutations in hypotrichosis with juvenile macular dystrophy. Clin Exp Dermatol. 2007;32(2):191–6.
7. Indelman M, Hamel CP, Bergman R, Nischal KK, Thompson D, Surget MO, et al. Phenotypic diversity and mutation spectrum in hypotrichosis with juvenile macular dystrophy. Clin Exp Dermatol. 2003;28(5):1217–20.
8. Indelman M, Leibu R, Jammal A, Bergman R, Sprecher E, Molecular basis of hypotrichosis with juvenile macular dystrophy in two siblings. Br J Dermatol. 2005;153(3):635–8.
9. Sprecher E, Bergman R, Richard G, Lurie R, Shalev S, Petronius D, et al. Hypotrichosis with juvenile macular dystrophy is caused by a mutation in CDH3, encoding P-cadherin. Nat Genet. 2001;29(2):134–6.
10. Jeleni M, Salman Chisti M, Ahmad W. A novel splice-site mutation in the CDH3 gene in hypotrichosis with juvenile macular dystrophy. Clin Exp Dermatol. 2009;34(1):68–73.
11. Kamran-ul-Hassan Naqvi S, Azeem Z, Ali G, Ahmad W. A novel splice-acceptor site mutation in CDH3 gene in a consanguineous family exhibiting hypotrichosis with juvenile macular dystrophy. Arch Dermatol Res. 2010;302(9):701–3.
12. Bait S, Walli A, Aziz A, Muhammad N, Jeleni M, Ahmad W. Digenic inheritance of an autosomal recessive hypotrichosis in two consanguineous pedigrees. Clin Genet. 2011;79(3):273–81.
13. Avtian-Hersh E, Indelman M, Khramyi Z, Leibu R, Bergman R. A novel nonsense CDH3 mutation in hypotrichosis with juvenile macular dystrophy. Int J Dermatol. 2012;51(3):325–7.
14. Hallow S, Holt R, Németh AH, Downes SM. Homozygous deletion in CDH3 and hypotrichosis with juvenile macular dystrophy. Arch Ophthalmol. 2012;130(11):1490–2.
15. Hull S, Arno G, Robson AG, Broadgate S, Plagnol V, McKibbin M, et al. Characterization of CDH3-related congenital hypotrichosis with juvenile macular dystrophy. JAMA Ophthalmol. 2016;134(9):992–1000.
16. Ahmad F, Ali RH, Muhammad D, Nasir A, Umair M, Wali SM. Novel homozygous sequence variants in the CDH3 gene encoding P-cadherin underlying hypotrichosis with juvenile macular dystrophy in consanguineous families. Eur J Dermatol. 2016 [Epub ahead of print].
17. Efatoiki FZ, Cordoliani F, Pascal Regane P, Affontit-Demoge A. Hypotrichosis with juvenile macular dystrophy: Portuguese case. Dermatol Online J. 2016;22(6):1–3.
18. Kjaer KW, Hansen L, Schwabe GC, Marques-de-Faria AP, Eiberg H, Mundlos S, et al. Distinct CDH3 mutations cause ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome). J Med Genet. 2005;42(4):262–8.
19. Basel-Vanaghetti L, Pasmanik-Chor M, Lurie R, Yeheskel A, Kjaer KW. CDH3-related syndromes: report on a new mutation and overview of the genotype-phenotype correlations. Mol Syndromol. 2010;1(5):223–30.
20. Leibu R, Jermans A, Hartim G, Miller B, Sprecher E, Perlman I. Hypotrichosis with juvenile macular dystrophy: clinical and electrophysiological assessment of visual function. Ophthalmology. 2006;113(5):1841–7, e3.
21. Mason 3rd JO, Patel SA. A case of hypotrichosis with juvenile macular dystrophy. Retin Cases Brief Rep. 2015;9(2):164–7.
22. Singh MS, Broadgate S, Mathur R, Holt R, Halford S, MacLaren RE. Hypotrichosis and juvenile macular dystrophy caused by CDH3 mutation: a candidate disease for retinal gene therapy. Sci Rep. 2016;6:23674.
23. Khan AO, Bolz HJ. Phenotypic observations in “Hypotrichosis with juvenile macular dystrophy” (recessive CDH3 mutations). Ophthalmic Genet. 2016;37(3):301–6.
24. Bergman R, Sipir M, Sprecher E. Histopathology of hypotrichosis with juvenile macular dystrophy. Am J Dermatopathol. 2004;26(3):205–9.
25. van Roy F, Ben T, Jelani M, Heger C, Cell Mol Life Sci. 2008;65(23):3756–88.
26. Maugeri A, Klevering BJ, Rohrschneider K, Blankenagel A, Brunner HG, Dufman AT, et al. Mutations in the ABCA4 (ABCR) gene are the major cause of autosomal recessive cone-rod dystrophy. Am J Hum Genet. 2000;67(4):960–6.
27. Rivero-Alvarez R, Lopez-Martinez MA, Zemant J, Aguierre-Lamban J, Cantalapiedra D, Avila-Fernandez A, et al. Outcome of ABCA4 disease-associated alleles in autosomal recessive retinal dystrophies: retrospective analysis in 420 Spanish families. Ophthalmology. 2013;120(1):2332–7.
28. dal L, Neubauer BA, Trottier MA, Altmuller J, Schneeberger E. Increased probability of co-occurrence of two rare diseases in consanguineous families and resolution of a complex phenotype by next generation sequencing. PLoS One. 2016;11(1):e0146040.
29. Schwartz TD, Riggins CD, Lamm B, Elliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385(9967):509–16.
30. Weleber RG, Penkei ME, Wilson DJ, Kaushal S, Erker LR, Jensen L, et al. Results at 2 years after gene therapy for RPE65-deficient leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmology. 2016;123(7):1606–20.